Abstract:The outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 highlight the need for countermeasures to prevent future coronavirus pandemics. Given the unpredictable nature of spillover events, preparing antibodies with broad coronavirus-neutralizing activity is an ideal proactive strategy. Here, we investigated whether SARS-CoV-2 infection and vaccination could provide cross-neutralizing antibodies (nAbs) against zoonotic sarbecoviruses. We evaluated the cross-neutralizing profiles of plasma and monoclonal antibodies constructed from B cells from coronavirus disease 2019 (COVID-19) convalescents and vaccine recipients; against sarbecoviruses originating from bats, civets, and pangolins; and against SARS-CoV-1 and SARS-CoV-2. We found that the majority of individuals with natural infection and vaccination elicited broad nAb responses to most tested sarbecoviruses, particularly to clade 1b viruses, but exhibited very low cross-neutralization to SARS-CoV-1 in both natural infection and vaccination, and vaccination boosters significantly augmented the magnitude and breadth of nAbs to sarbecoviruses. Of the nAbs, several exhibited neutralization activity against multiple sarbecoviruses by targeting the spike receptor-binding domain (RBD) and competing with angiotensin-converting enzyme 2 (ACE2) binding. SCM12-61 demonstrated exceptional potency, with half-maximal inhibitory concentration (IC50) values of 0.001-0.091 μg/mL against tested sarbecoviruses; while VSM9-12 exhibited remarkable cross-neutralizing breadth against sarbecoviruses and SARS-CoV-2 Omicron subvariants, highlighting the potential of these two nAbs in combating sarbecoviruses and SARS-CoV-2 Omicron subvariants. Collectively, our findings suggest that vaccination with an ancestral SARS-CoV-2 vaccine, in combination with broad nAbs against sarbecoviruses, may provide a countermeasure for preventing further sarbecovirus outbreaks in humans.

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models

Designed mosaic nanoparticles enhance cross-reactive immune responses in mice

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models

Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses

Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine

A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses

Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2

A Single Chimeric Spike Antigen Induces Pan-Sarbecovirus Immunity

A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans

Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability

An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models